Evergreen Capital Management LLC Sells 3,547 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Evergreen Capital Management cut its Regeneron position by 20%, selling 3,547 shares and retaining 14,214 shares valued at approximately $10.8 million. Institutional investors and hedge funds collectively own 83.31% of the company.
• Regeneron reported quarterly EPS of $14.29, exceeding estimates of $10.16, while revenue rose 16.7% year over year to $4.29 billion. The company also paid a $0.94 quarterly dividend, equivalent to a 0.5% yield.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $846.28, although insiders sold 8,093 shares worth roughly $6.5 million over the past 90 days.

Evergreen Capital Management LLC lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 20.0% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,214 shares of the biopharmaceutical company's stock after selling 3,547 shares during the period. Evergreen Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $10,778,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $26,000. Armstrong Advisory Group Inc. boosted its position in Regeneron Pharmaceuticals by 466.7% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $29,000. Trust Co. of Vermont bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $29,000. Finally, Fiduciary Financial Advisors bought a new position in Regeneron Pharmaceuticals during the 2nd quarter worth $29,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares of the company's stock, valued at approximately $512,550. This trade represents a 39.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the firm's stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the transaction, the insider directly owned 47,833 shares in the company, valued at approximately $36,960,559.10. The trade was a 7.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 8,093 shares of company stock valued at $6,506,845 in the last ninety days. Company insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Stock Down 1.7%

REGN opened at $805.02 on Friday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $575.93 and a 12 month high of $859.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The stock has a market cap of $82.88 billion, a P/E ratio of 19.90, a P/E/G ratio of 1.36 and a beta of 0.16. The stock's 50 day moving average price is $791.86 and its 200 day moving average price is $723.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the firm posted $12.81 EPS. The firm's quarterly revenue was up 16.7% on a year-over-year basis. As a group, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 49.10 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 9.29%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Sanford C. Bernstein increased their target price on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the stock a "market perform" rating in a research report on Friday, August 14th. Truist Financial increased their price objective on shares of Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the stock a "buy" rating in a report on Wednesday, October 7th. UBS Group upgraded shares of Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $660.00 to $978.00 in a research report on Thursday, October 15th. Morgan Stanley lifted their price objective on shares of Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 7th. Finally, Zacks Research raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 28th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have given a Hold rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $846.28.

Key Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: TD Cowen raised its price target to $980 from $960 while maintaining a positive view of Regeneron, signaling potential upside from current levels. TD Cowen raises target for Regeneron stock
• Positive Sentiment: Analysts and investors continue to point to Regeneron’s growth potential, including strong Dupixent performance and positive Phase 3 OPTIMA results for investigational pasatru in fibrodysplasia ossificans progressiva. The company is also working to build a broader global oncology business. Regeneron growth potential analysis
• Neutral Sentiment: Regeneron is scheduled to report quarterly results next week. Analysts expect earnings to grow, but the company reportedly lacks the typical combination of estimate revisions and other indicators associated with a likely earnings beat, creating uncertainty ahead of the release. Regeneron earnings expectations
• Neutral Sentiment: Recent coverage describes REGN as a relatively steady stock and notes that it gained in the prior session, although it lagged some competitors. This provides limited new information about the company’s fundamentals. Regeneron stock performance versus competitors
• Negative Sentiment: Valuation-related commentary asks whether Regeneron is priced too highly relative to pharmaceutical peers, which could limit near-term upside and encourage profit-taking ahead of earnings. Regeneron valuation versus rivals

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.